GlassScriptPhysician profile
Heather A Prusik
NPI 1336419829
$2,076.38
in general payments reported to CMS, 2019-2025
19 companies · $993 in 2025
The $993 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $488 · 2024: $595 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $630.22 | 2023-2025 | |
| Novo Nordisk INC | $283.60 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $185.77 | 2023-2024 | Repatha, Prolia, Evenity |
| Lilly USA, LLC | $159.96 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $157.14 | 2023-2025 | |
| Dexcom, INC. | $148.13 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astellas Pharma US INC | $101.24 | 2023-2025 | Veozah |
| Tris Pharma INC | $74.01 | 2023-2024 | Dyanavel Xr |
| Exact Sciences Corporation | $55.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $46.66 | 2023 | |
| Gilead Sciences, INC. | $44.92 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.06 | 2023-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $35.61 | 2023-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.76 | 2025 | Jardiance |
| Noven Therapeutics, LLC | $19.93 | 2023 | Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.22 | 2024 | Interstim |
| Merck Sharp & Dohme LLC | $17.36 | 2025 | Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $17.29 | 2023 | Rexulti |
| Seqirus USA INC | $14.96 | 2024 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Prusik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.